Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Depreciation & Amortization (CF) came in at $46000.0 in Q2 2026, up 24.32% YoY from $37000.0 in Q2 2025, and up 4.55% on a QoQ basis from $44000.0 in Q1 2026.
Summit Therapeutics (SMMT) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $46000.0 in Q2 2026.
- Quarterly Depreciation & Amortization (CF) rose 24.32% year-over-year to $46000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $174000.0 (up 67.31% YoY) and the FY2025 annual result came in at $146000.0, up 64.04% from the prior year.
- Depreciation & Amortization (CF) grew to $46000.0 in Q2 2026, from $44000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $99000.0 in Q2 2022 to a low of $20000.0 in Q2 2024.
- A 5-year average of $48444.4 and a median of $42000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 70.0% — and 2025, when it soared 110.0%.
- Tracing SMMT's Depreciation & Amortization (CF) over 5 years: stood at $88000.0 in 2022, then slumped by 65.91% to $30000.0 in 2023, then fell by 26.67% to $22000.0 in 2024, then jumped by 90.91% to $42000.0 in 2025, then climbed by 9.52% to $46000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $46000.0 (Q2 2026), $44000.0 (Q1 2026), and $42000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 46,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46,000.00 |
| Jun 30, 2026 | 46,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 37,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Mar 31, 2024 | 27,000.00 |